BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 25972048)

  • 1. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.
    Yeung MW; Young J; Moodie E; Rollet-Kurhajec KC; Schwartzman K; Greenaway C; Cooper C; Cox J; Gill J; Hull M; Walmsley S; Klein MB
    HIV Clin Trials; 2015; 16(3):100-10. PubMed ID: 25972048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.
    Young J; Rossi C; Gill J; Walmsley S; Cooper C; Cox J; Martel-Laferriere V; Conway B; Pick N; Vachon ML; Klein MB;
    Clin Infect Dis; 2017 May; 64(9):1154-1162. PubMed ID: 28199495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
    Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
    Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Kovari H; Rauch A; Kouyos R; Rougemont M; Cavassini M; Schmid P; Stöckle M; Bernasconi E; Weber R; Ledergerber B;
    Clin Infect Dis; 2017 Feb; 64(4):490-497. PubMed ID: 28172403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.
    Gormley MA; Akiyama MJ; Rennert L; Howard KA; Norton BL; Pericot-Valverde I; Muench S; Heo M; Litwin AH
    Clin Infect Dis; 2022 May; 74(9):1586-1593. PubMed ID: 34331539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.
    Casado JL; Esteban MA; Bañón S; Moreno A; Perez-Elías MJ; Mateos ML; Moreno S; Quereda C
    Dig Dis Sci; 2015 Nov; 60(11):3473-81. PubMed ID: 26112991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Sikavi C; Najarian L; Saab S
    Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
    Solà R; Galeras JA; Montoliu S; Tural C; Force L; Torra S; Montull S; Castro ER; Coll S; Fuster D; Barrufet P; Sirera G; Giménez MD; Clotet B; Planas R
    AIDS Res Hum Retroviruses; 2006 May; 22(5):393-400. PubMed ID: 16706615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.